4 completed, 2 recruiting, 1 active not recruiting. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Cobicistat: new trials by email Literature Review of Cobicistat trials Research Report on Cobicistat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML azacitidine, Venetoclax, Cobicistat - AML, Adult | Phase 2 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 142 | 2024-01-17 | 2026-09-23 |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation revumenib, cobicistat - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Syndax Pharmaceuticals | 447 | 2019-11-05 | 2026-10-09 |
| ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer CPI-1205, Cobicistat, Enzalutamide - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 175 | 2017-11-15 | 2025-10-29 |
| Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults GSK2838232, Cobicistat - Infection, Human Immunodeficiency Virus, HIV Infections | Phase 2 | Completed | GlaxoSmithKline | 33 | 2017-03-17 | 2020-03-11 |
| Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV ATV, DRV, Cobicistat - Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | Phase 2 / Phase 3 | Active not recruiting | Gilead Sciences | 133 | 2014-01-16 | 2026-04-21 |
| D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults D/C/F/TAF, DRV, COBI - Acquired Immunodeficiency Syndrome, HIV Infections | Phase 2 | Completed | Gilead Sciences | 153 | 2012-04-01 | 2016-04-11 |
| Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults COBI, RTV, ATV - HIV-1 Infection | Phase 2 | Completed | Gilead Sciences | 85 | 2009-05-01 | 2016-02-15 |
Acquired Immunodeficiency Syndrome (3) · HIV Infections (3) · Leukemia, Myeloid, Acute (2) · Infections (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Gilead Sciences (3) · Constellation Pharmaceuticals (1) · GlaxoSmithKline (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Syndax Pharmaceuticals (1)
United States (6) · Canada (2) · Netherlands (2) · Puerto Rico (2) · Argentina (1) · Australia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Lithuania (1) · South Africa (1) · Spain (1) · Thailand (1) · Uganda (1)
Angela R Smith, M.D. (1) · Marshall Fordyce, MD (1) · Moupali Das, MD, MPH (1)
PMID 21811136, PMID 33741715, PMID 34267079, PMID 36922593, PMID 39121437, PMID 40332046, PMID 41621809, PMID 42007248
2023 (1)